mdt-31 Antibody

What is IL-31 and why is it a significant target for antibody development?

IL-31 is an interleukin that functions as a key mediator in multiple pruritic skin conditions. Research indicates that IL-31 acts through the IL-31 receptor A, making it a critical target for therapeutic antibody development. As evidenced in clinical trials, targeting the IL-31 signaling pathway can significantly reduce pruritus and improve associated conditions. For instance, nemolizumab, a monoclonal antibody targeting IL-31 receptor A, demonstrated significant efficacy in reducing pruritus in patients with prurigo nodularis, with a 53% reduction in peak pruritus score after just 4 weeks compared to 20% with placebo . Researchers investigating this pathway should understand that IL-31 is part of a complex inflammatory cascade that influences both neuronal sensitization and skin barrier function.

What are the standard validation methods for confirming IL-31 antibody specificity?

Validating IL-31 antibody specificity requires multiple complementary approaches:

• Western blotting against recombinant IL-31 protein and tissue lysates known to express IL-31

• ELISA-based validation using concentration gradients to establish specificity curves

• Immunohistochemistry with appropriate positive and negative controls

• Antibody blocking experiments using recombinant IL-31 protein

• Cross-reactivity testing against structurally similar cytokines

When performing validation, researchers should include isotype controls, as recommended for antibodies like anti-CD31 (e.g., purified rat IgG2a for the MEC13.3 antibody) . Validation should be conducted across multiple lots of antibody and in the specific sample types planned for experimental use.

How do IL-31 antibodies compare with other tools for studying IL-31-mediated pathways?

IL-31 antibodies offer unique advantages for protein detection in biological samples, while complementary approaches like the auxin-inducible degradation system demonstrated with UNC-31 can provide temporal control over protein expression . Researchers should select methods based on specific experimental questions.

What are the optimal conditions for using IL-31 antibodies in immunohistochemistry?

Optimizing immunohistochemistry with IL-31 antibodies requires careful consideration of multiple variables:

• Tissue fixation: The fixation method significantly impacts epitope accessibility. For example, with some antibodies like anti-CD31 (MEC13.3), zinc fixation for paraffin sections is recommended over formalin fixation . For IL-31 antibodies, compare acetone, PFA, and methanol fixation to determine optimal epitope preservation.

• Antigen retrieval: Test multiple retrieval methods (heat-induced epitope retrieval with citrate buffer pH 6.0 vs. EDTA buffer pH 9.0, or enzymatic retrieval with proteinase K).

• Detection system: A three-step staining procedure is often optimal, similar to that recommended for the MEC13.3 antibody: primary antibody, biotinylated secondary antibody, and streptavidin-HRP .

• Antibody titration: Always titrate antibodies to determine optimal concentration. For example, the MEC13.3 anti-CD31 antibody is recommended at dilutions of 1:10 to 1:50 .

• Controls: Include both positive controls (tissues known to express IL-31) and negative controls (isotype-matched irrelevant antibodies).

When adapting protocols from CD31 staining to IL-31 pathway components, researchers should perform systematic optimization for each parameter independently.

How can researchers troubleshoot inconsistent results when using IL-31 antibodies?

Troubleshooting inconsistent antibody results requires systematic evaluation of multiple factors:

• Antibody integrity: Check for degradation by running a small aliquot on SDS-PAGE. Store antibodies according to manufacturer recommendations and avoid repeated freeze-thaw cycles.

• Sample preparation: Inconsistent protein extraction or fixation can significantly impact results. Standardize preparation protocols and processing times.

• Technical variables: Control for incubation times, temperatures, and buffer compositions. Even minor variations can affect binding kinetics.

• Cross-reactivity: Test for potential cross-reactivity with other proteins in your experimental system, particularly other interleukin family members.

• Endogenous binding interference: Consider the use of blocking reagents specifically designed to reduce non-specific binding.

• Lot-to-lot variation: When receiving a new antibody lot, perform side-by-side validation with previous lots using positive control samples.

Documentation of all experimental parameters is crucial for identifying sources of variability. Create detailed laboratory protocols that include specific handling instructions and quality control checkpoints.

What approaches can be used to study the temporal dynamics of IL-31 signaling?

Understanding the temporal dynamics of IL-31 signaling requires specialized approaches:

• Conditional degradation systems: The auxin-inducible degradation system demonstrated with UNC-31 provides precise temporal control over protein expression . This approach could be adapted to IL-31 pathway components by creating degron-tagged constructs.

• Real-time imaging: Fluorescently tagged IL-31 or receptor constructs enable visualization of trafficking and internalization dynamics following stimulation.

• Phosphorylation kinetics: Temporal analysis of downstream signaling components using phospho-specific antibodies at defined time points post-stimulation reveals activation patterns.

• Inducible expression systems: Tet-ON/OFF or similar systems allow controlled expression of IL-31 or receptor components to study initiation of signaling.

• Single-cell analysis: Combined with flow cytometry or imaging, this approach reveals population heterogeneity in response timing and magnitude.

The temporal resolution of these methods varies significantly. For instance, the auxin-inducible degradation system allows protein depletion and recovery on the scale of hours to days , while phosphorylation events occur within minutes of receptor activation.

How are IL-31 antibodies being developed as therapeutic agents?

The development of IL-31-targeting therapeutic antibodies follows a rigorous process:

• Target validation: Extensive preclinical research establishes IL-31's role in disease pathology. For example, studies have identified IL-31 as a critical mediator in prurigo nodularis .

• Antibody humanization: Similar to TB31F, a humanized monoclonal antibody developed for malaria, IL-31 targeting antibodies must undergo humanization to reduce immunogenicity in patients .

• Clinical testing: Progression through phase trials evaluating safety and efficacy. Nemolizumab, an IL-31 receptor A targeting antibody, demonstrated significant efficacy in a phase II clinical trial for prurigo nodularis, with patients showing a 53% reduction in pruritus score compared to 20% with placebo after 4 weeks of treatment .

• Dosing optimization: Determining optimal dosing regimens and routes of administration. For instance, nemolizumab was evaluated in a phase II study to determine efficacy and safety profiles , while other antibodies like TB31F have been tested at various dose levels (0.1, 1, 3, and 10 mg/kg intravenously and 100 mg subcutaneously) .

• Long-term monitoring: Assessment of sustained efficacy and safety through extended follow-up. As seen with nemolizumab, effects on lesion reduction persisted through the last follow-up visit at week 18 (10 weeks after the final dose) .

These therapeutic antibodies represent a significant advancement for conditions with limited treatment options, as highlighted by researchers noting that "the pharmaceutical development of novel therapies which might receive a label is highly needed" .

What methods are used to assess IL-31 antibody pharmacokinetics in clinical trials?

Assessment of IL-31 antibody pharmacokinetics in clinical settings involves multiple approaches:

• ELISA-based quantification: Serum concentrations can be measured by ELISA against target antigens, similar to the method used for TB31F, where antibody concentrations were quantified with ADAMSEL software using a standard curve and multiple serum dilutions .

• Detection limits optimization: Sensitivity varies based on serum dilutions tested. For example, TB31F studies established different detection limits based on dosing group: 0.039 μg/mL for the 0.1 mg/kg group, 0.39 μg/mL for the 1 mg/kg and 100 mg subcutaneous groups, 1.17 μg/mL for the 3 mg/kg group, and 3.91 μg/mL for the 10 mg/kg group .

• Antidrug antibody monitoring: Development of antidrug antibodies can significantly affect pharmacokinetics and should be assessed by sandwich ELISA, as was done in the TB31F trial .

• Functional persistence assays: The duration of therapeutic effect can be estimated through functional assays at extended timepoints post-administration. TB31F, for example, demonstrated activity estimated to last up to 5 months after a single administration .

• Tissue distribution studies: When feasible, assessing antibody penetration into target tissues provides insights into bioavailability at the site of action.

These pharmacokinetic data are crucial for establishing dosing intervals and understanding the relationship between serum concentrations and clinical efficacy.

What are the challenges in translating IL-31 antibody research from animal models to human applications?

Translating IL-31 antibody research from preclinical models to human applications presents several challenges:

• Species differences in IL-31 biology: Variations in IL-31 sequence, expression patterns, and signaling pathways between species can affect antibody cross-reactivity and functional outcomes. Researchers must consider these differences when using antibodies like anti-mouse CD31, which has defined species reactivity limitations .

• Model fidelity: Animal models may not fully recapitulate the complex pathophysiology of human diseases, particularly for multifactorial conditions involving IL-31 signaling.

• Dosing translation: Allometric scaling from animal to human dosing requires careful consideration of differences in metabolism, distribution, and clearance. Clinical trials typically employ dose-escalation designs, as seen with TB31F (0.1, 1, 3, and 10 mg/kg intravenously) .

• Safety prediction: Adverse events in humans may not be predicted by preclinical models. As a precautionary measure, clinical trials often implement safety monitoring protocols, such as the premedication with paracetamol and clemastine used in the TB31F trial .

• Target validation: Confirming that the role of IL-31 in human disease matches observations in animal models is essential. The successful clinical outcomes with nemolizumab validate IL-31 receptor targeting in prurigo nodularis .

Researchers must employ multiple complementary approaches to address these challenges, including humanized mouse models, ex vivo human tissue studies, and careful first-in-human study designs with robust safety monitoring.

What techniques are most effective for measuring IL-31 antibody binding kinetics?

Several advanced techniques provide detailed insights into IL-31 antibody binding kinetics:

• Surface Plasmon Resonance (SPR): Provides real-time, label-free measurement of association and dissociation rates. This technique can determine kon, koff, and KD values with high precision.

• Bio-Layer Interferometry (BLI): Offers similar data to SPR but with different technical advantages, particularly for crude sample analysis.

• Isothermal Titration Calorimetry (ITC): Measures thermodynamic parameters of binding, providing insights into the enthalpy and entropy contributions.

• Microscale Thermophoresis (MST): Requires minimal sample amounts and can measure interactions in complex biological matrices.

• Competitive ELISA approaches: Though less precise for kinetic constants, these can provide relative affinity measurements across multiple antibodies.

When designing these experiments, researchers should consider that binding characteristics may vary depending on whether the antibody targets soluble IL-31 or membrane-bound IL-31 receptor. Additionally, the experimental conditions (buffer composition, pH, temperature) should mimic physiological conditions as closely as possible to obtain biologically relevant binding parameters.

How should researchers design experiments to study IL-31 antibody effects in cellular systems?

Designing robust cellular experiments for IL-31 antibody studies requires careful consideration:

• Cell line selection: Choose cell lines that endogenously express IL-31 receptors or create stable transfectants with defined receptor expression levels. Validate receptor expression using flow cytometry or western blotting.

• Stimulation protocols: Establish dose-response relationships for recombinant IL-31 stimulation before testing antibody-mediated inhibition. Include time-course studies to capture both immediate and delayed responses.

• Readout selection: Select appropriate assays based on known IL-31 signaling outcomes:

  • Phosphorylation of STAT proteins (Western blot, flow cytometry)

  • Transcriptional changes in IL-31-responsive genes (qPCR, RNA-seq)

  • Functional outcomes like cell migration or cytokine production

• Antibody controls: Include isotype-matched control antibodies at equivalent concentrations to distinguish specific from non-specific effects, similar to recommendations for other antibodies like anti-CD31 .

• Validation approaches: For knockout or knockdown validation, consider regulated systems like the auxin-inducible degradation system demonstrated with UNC-31, which allows temporal control of protein depletion .

What considerations are important when using IL-31 antibodies in multi-color flow cytometry?

Optimizing IL-31 antibodies for multi-color flow cytometry requires attention to several technical aspects:

• Panel design: Consider the spectral properties of fluorophores conjugated to the IL-31 antibody and avoid combinations with significant spectral overlap. Design panels that include markers to identify relevant cell populations expressing IL-31 receptors.

• Titration optimization: Perform careful antibody titration to determine the optimal concentration that maximizes the signal-to-noise ratio. This is particularly important for detecting molecules with potentially low expression levels.

• Controls: Include:

  • Fluorescence minus one (FMO) controls

  • Isotype controls at matching concentrations

  • Positive controls (cells known to express the target)

  • Negative controls (cells known not to express the target)

• Fixation compatibility: Test whether the IL-31 antibody epitope is preserved under different fixation conditions if intracellular staining is required.

• Buffer optimization: Some antibodies perform better in specific buffer compositions. Test performance in standard flow cytometry buffers versus specialized formulations.

• Compensation: Proper compensation is critical in multi-color panels. Use single-color controls with the same fluorophores used in the full panel on the same cell type when possible.

When analyzing rare populations or molecules with low expression levels, consider signal amplification systems or alternative approaches like mass cytometry if conventional flow cytometry lacks sufficient sensitivity.

How can spatiotemporal control systems enhance IL-31 pathway research?

Advanced spatiotemporal control systems offer powerful new approaches for IL-31 research:

• Conditional degradation systems: The auxin-inducible degradation system demonstrated with UNC-31 could be adapted to IL-31 pathway components. This approach enables "protein degradation in various tissues and at distinct developmental stages" with protein depletion within hours of auxin treatment . Similar systems could allow precise temporal manipulation of IL-31 signaling components.

• Cell-specific manipulation: Targeted expression of regulatory components in specific cell populations provides spatial control. For example, depleting a signaling component "specifically from the BAG sensory neurons" revealed cell-specific functions , an approach that could identify cell-specific roles of IL-31 signaling.

• Optogenetic control: Light-inducible systems can activate or inhibit IL-31 signaling with precise temporal and spatial resolution, enabling studies of local signaling events.

• Chemogenetic approaches: Chemical-inducible systems provide intermediate temporal control compared to genetic and optogenetic methods.

• Multi-modal imaging: Combining functional reporters with structural markers enables correlation between IL-31 pathway activation and cellular consequences.

These approaches address the need for "precise manipulation of neuropeptide release" noted in UNC-31 research, which similarly applies to cytokine signaling systems like IL-31 . The development of these tools will enable researchers to examine IL-31 function "at exceptional resolution" in complex biological systems .

What are the most promising emerging applications of IL-31 antibodies beyond dermatology?

IL-31 antibody research is expanding beyond dermatological applications into several promising areas:

• Neuroinflammatory conditions: Given IL-31's role in neuronal sensitization, antibodies targeting this pathway may have applications in neuropathic pain and neuroinflammatory disorders.

• Respiratory diseases: Emerging evidence suggests IL-31 signaling contributes to airway inflammation and remodeling in asthma and chronic obstructive pulmonary disease.

• Gastrointestinal disorders: IL-31 may mediate visceral hypersensitivity in irritable bowel syndrome and inflammatory bowel disease, suggesting therapeutic potential for IL-31 antibodies.

• Cancer immunotherapy: Preliminary research indicates IL-31 may modulate tumor microenvironments, offering potential applications in combination cancer therapies.

• Diagnostic biomarkers: Beyond therapeutic applications, IL-31 antibodies may serve as diagnostic tools to identify patients likely to respond to targeted therapies or monitor disease progression.

These applications build on successful clinical outcomes seen with IL-31 pathway-targeting antibodies like nemolizumab, which demonstrated significant efficacy in prurigo nodularis . As with other therapeutic antibodies, these applications will require rigorous clinical evaluation through well-designed trials with appropriate safety monitoring.

What are the key considerations for researchers new to IL-31 antibody applications?

Researchers entering the field of IL-31 antibody research should consider these essential points:

• Antibody validation is critical: Comprehensively validate antibodies using multiple complementary approaches before conducting major experiments. Establish specificity, sensitivity, and optimal working conditions for each application.

• Context matters: IL-31 signaling operates within complex cellular networks. Consider the broader signaling environment and potential cross-talk with other pathways when interpreting results.

• Translational relevance: When designing research questions, consider how findings might inform clinical applications. The success of nemolizumab in clinical trials demonstrates the translational potential of basic IL-31 pathway research .

• Technical challenges require optimization: Each application (Western blot, IHC, flow cytometry) may require specific optimization for IL-31 antibodies. Invest time in method development before conducting critical experiments.

• Collaborative approach: Given the complexity of IL-31 biology and antibody technology, collaborations across immunology, dermatology, neuroscience, and antibody engineering can accelerate progress.